News | May 14, 2025
Sai Life Sciences FY25 PAT higher by 105% to Rs. 170 Cr
PAT stood at Rs. 88 crore for Q4 FY25 as compared to Rs. 56 crore in Q4FY24, an increase of 57%
PAT stood at Rs. 88 crore for Q4 FY25 as compared to Rs. 56 crore in Q4FY24, an increase of 57%
RPG Life Sciences has reported total income of Rs. 148.15 crores during the period ended March 31, 2025
The partnership provides Sai Life Sciences with a greenhouse gas emissions reduction of up to 90% for its international logistics needs by using SAF
Introduces revolutionary approach to workflow management to enhance operational efficiency and optimize process efficiency
Increases Siemens’ industrial software total addressable market by $11 billion; aligns with strategic goal to accelerate customer innovation across industries
The Peptide Research Center is designed to support innovator pharma and biotech companies with specialized services across peptide synthesis, discovery, and advanced modalities, including complex conjugates
The consignment of USFDA qualified Metformin (1000mg) was received by the province of Mendoza for distribution in the public health system
RPG Life Sciences has reported total income of Rs. 176.02 crore during the period ended December 31, 2024
EBITDA margins expand to 31.3%
The change is reflective of the company’s evolving vision aimed at further strengthening its global presence and a commitment to providing innovative solutions in the API and CDMO space
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
